Anormed, Inc.

Genzyme Corporation

Aquinox Pharmaceuticals (canada) Inc.

Xenon Pharmaceuticals Inc.

Apogee Pharmaceuticals, Inc.

Aquinox Pharmaceuticals Inc.

David Earl Bogucki

Gary James Bridger

Dominique Schols

Curtis Harwig

Renato Skerlj

Yuanxi Zhou

Siqiao Nan

Ernest John McEachern

Al Kaller

Jason B Crawford

Trevor R Wilson

Bem Atsma

Maria Rosaria Di Fluri

Christopher Dennis Smith

Eva Maria Boehringer

Zhongren Wang

Jeremy D Pettigrew

Jeffery R Raymond

Lloyd F Mackenzie

Thomas B MacRury

Vladimir Khlebnikov

Renato Tony Skerlj

Rudong Shan

Bern Atsma

Christopher Dennis

Rosaria Maria Di Fluri

Markus Metz

Tong-Shuang Li

Elyse Bourque

Wen Yang

Jonathan Langille

Ernest J Mceachern

Christoph Martin Dehnhardt

Sultan Chowdhury

Thilo Focken

Qi Jia

Alla Yurevna Zenova

Michael Edward Grimwood

Robert Joseph Devita

Michael Scott Wilson

Jean-Christophe Andrez

Kristen Nicole Burford

Shannon Marie Decker

Syed Abid Hasan

James Philip Johnson, Jr

Charles Jay Cohen

James Roy Empfield

Kaiji Hu

Safwat Mohamed Rabea

Renato T Skelj

Maria Rosario DiFluri

Renato T Skerlj

Trevor Wilson

James Philip Johnson

Siquiao Nan

Jr Johnson James Philip

Disclosed are compounds of Formula I that are useful as Monoacylglycerol lipase (MAGL) inhibitors These compounds may be used in pharmaceutical compositions, formulations, and methods for the treatment of disease states, disorders, and conditions benefited by the inhibition or modulation of MAGL activity, such as, but are not limited to, anxiety and mood disorder, metabolic disorder, a neurodegenerative disorder, mental disorder, brain disorder, pain, inflammatory disorder, cancer, Alzheimer's disease, movement disorders, epilepsy or stroke.

Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.

Benzenesulfonamide compouds and their use as therapeutic agents

The invention relates to heterocyclic compounds consisting of a core nitrogen atom surrounded by three pendant groups, wherein two of the three pendant groups are preferably benzimidazolyl methyl and tetrahydroquinolyl, and the third pendant group contains N and optionally contains additional rings. The compounds bind to chemokine receptors, including CXCR4 and CCR5, and demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding heterocyclic compounds with enhanced efficacy

Compounds of formula (I): where n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

SHIP1 modulators and methods related thereto

Compounds of formula (II): wherein R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof.

Compounds of formula (I): where R, R, R, R, R, R, Rand Rare defined herein, or stereoisomers or pharmaceutically acceptable salts thereof, are described herein. Such compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Compounds of formula (II): wherein A, R, R, Rand Rare described herein, or a stereoisomer, enantiomer or tautomer thereof or mixtures thereof, or a pharmaceutically acceptable salt or solvate thereof, are described herein, as well as other compounds. These compounds have activity as SHIP1 modulators, and thus may be useful in treating a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of the invention are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Compounds of formula (I): where, n, R, R, R, R, Rand Rare defined herein, or pharmaceutically acceptable salts thereof, are described herein. The disclosed compounds have activity as SHIP1 modulators, and thus may be used to treat any of a variety of diseases, disorders or conditions that would benefit from SHIP1 modulation. Compositions comprising a compound of formula (I) in combination with a pharmaceutically acceptable carrier or diluent are also disclosed, as are methods of SHIP1 modulation by administration of such compounds to an animal in need thereof. 

Compounds which modulate chemokine receptor activities are disclosed. These compounds are preferably tertiary amines comprising tetrahydroquinoline and benzimidazole.

Chemokine receptor binding heterocyclic compounds

The present invention is drawn to novel antiviral compounds, pharmaceutical compositions and their use. More specifically this invention is drawn to derivatives of monocyclic polyamines which have activity in standard tests against HIV- or FIV-infected cells as well as other biological activity related to binding of ligands to chemokine receptors that mediate a number of mammalian embryonic developmental processes.

CXCR4 antagonists

Heterocyclic compounds that bind chemokine receptors and inhibit the binding of their natural ligands are disclosed. The invention compounds are protective against infection by HIV and exert effects characteristic of antagonists to the CXCRreceptor.

The present invention relates to chemokine receptor binding compounds, pharmaceutical compositions and their use. More specifically, the present invention relates to modulators of chemokine receptor activity, preferably modulators of CCR5. These compounds demonstrate protective effects against infection of target cells by a human immunodeficiency virus (HIV).

Chemokine receptor binding compounds

Growing community of inventors

Surrey, Canada

David Earl Bogucki